Drug intelligence / Profile preview

EDIRA088 + EDIRA092 + EDIRA083

Development stage: Preclinical
Lead developer: Centre d’Immunologie et des Maladies Infectieuses
Modality: Live Biotherapeutic Products → Microbiome Therapeutics

Overview

EDIRA088 + EDIRA092 + EDIRA083 is an experimental, unapproved antibacterial phage therapy cocktail consisting of three lytic bacteriophages (EDIRA083, EDIRA088, and EDIRA092) isolated from sewage and environmental water samples. These phages belong to distinct genera within the Caudoviricetes class (formerly Siphoviridae family) and target multidrug-resistant (MDR), extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae strains, specifically those causing recurrent urinary tract infections (UTIs). EDIRA083 and EDIRA092 target the bacterial capsule, lipopolysaccharide (LPS), and the maltoporin LamB as receptors, while EDIRA088 targets a different, distinct receptor. The cocktail has demonstrated synergistic lytic activity in vitro, with enhanced and sustained bacterial killing in human urine compared to standard Luria-Bertani (LB) medium.

Other names: EDIRA083 + EDIRA088 + EDIRA092

Targets

LPS (Lipopolysaccharide)CPS (Streptococcus pneumoniae capsular polysaccharide)LamB (Maltoporin)

Beyond the preview

Go deeper on EDIRA088 + EDIRA092 + EDIRA083.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDIRA088 + EDIRA092 + EDIRA083.